Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Miragen Therapeutics (MGEN) Competitors

Miragen Therapeutics logo

MGEN vs. XGN, MDXH, SERA, OPGN, BDSX, BNR, ENZ, BGLC, ACON, and NTRA

Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Exagen (XGN), MDxHealth (MDXH), Sera Prognostics (SERA), OpGen (OPGN), Biodesix (BDSX), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA).

Miragen Therapeutics vs.

Exagen (NASDAQ:XGN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Exagen had 3 more articles in the media than Miragen Therapeutics. MarketBeat recorded 3 mentions for Exagen and 0 mentions for Miragen Therapeutics. Exagen's average media sentiment score of 0.89 beat Miragen Therapeutics' score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company Overall Sentiment
Exagen Positive
Miragen Therapeutics Neutral

Exagen currently has a consensus target price of $7.50, suggesting a potential upside of 7.45%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Miragen Therapeutics received 239 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 62.22% of users gave Exagen an outperform vote.

CompanyUnderperformOutperform
ExagenOutperform Votes
28
62.22%
Underperform Votes
17
37.78%
Miragen TherapeuticsOutperform Votes
267
70.45%
Underperform Votes
112
29.55%

Exagen has higher revenue and earnings than Miragen Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$56.72M2.62-$23.69M-$0.84-8.31
Miragen Therapeutics$4.46M12.24-$41.87M-$20.09-0.70

75.3% of Exagen shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Exagen has a net margin of -30.36% compared to Miragen Therapeutics' net margin of -1,393.50%. Exagen's return on equity of -92.58% beat Miragen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-30.36% -92.58% -33.74%
Miragen Therapeutics -1,393.50%-141.66%-88.74%

Exagen has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Summary

Exagen beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks.

Get Miragen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGEN vs. The Competition

MetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$54.60M$2.96B$5.38B$8.46B
Dividend YieldN/A31.27%5.28%4.17%
P/E Ratio-1.3112.9427.0619.79
Price / Sales12.24159.75402.10137.54
Price / CashN/A57.5638.2534.64
Price / Book2.064.406.844.53
Net Income-$41.87M-$22.21M$3.22B$247.85M

Miragen Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGEN
Miragen Therapeutics
N/A$13.97
+3.5%
N/A+12.7%$54.60M$4.46M-1.3145High Trading Volume
XGN
Exagen
3.75 of 5 stars
$5.88
-7.1%
$7.50
+27.6%
+265.4%$125.24M$56.72M-6.26220Short Interest ↑
MDXH
MDxHealth
2.8104 of 5 stars
$2.20
+6.3%
$6.50
+195.5%
-21.2%$104.03M$94.51M-1.45300Positive News
SERA
Sera Prognostics
0.8127 of 5 stars
$2.18
-6.0%
N/A-82.9%$82.50M$115,000.00-2.21120
OPGN
OpGen
N/A$4.89
flat
N/A+34.5%$49.23M$2.67M0.00100News Coverage
Upcoming Earnings
BDSX
Biodesix
3.3416 of 5 stars
$0.28
-7.6%
$2.00
+619.4%
-76.2%$39.43M$71.32M-0.69220Short Interest ↑
BNR
Burning Rock Biotech
1.2362 of 5 stars
$2.96
+8.6%
N/A-59.2%$31.80M$515.82M-0.991,390Upcoming Earnings
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-74.0%$17.03M$29.09M0.00520Gap Down
High Trading Volume
BGLC
BioNexus Gene Lab
0.1054 of 5 stars
$2.68
-0.4%
N/A-20.8%$4.82M$9.51M0.0030Negative News
Short Interest ↑
ACON
Aclarion
2.3728 of 5 stars
$7.00
-2.4%
$11,758.50
+167,878.6%
-99.8%$4.07M$45,724.000.007News Coverage
Short Interest ↓
NTRA
Natera
3.0765 of 5 stars
$154.01
+0.5%
$182.12
+18.2%
+43.9%$21.00B$1.83B-87.393,020Positive News

Related Companies and Tools


This page (NASDAQ:MGEN) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners